Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | INSR | P06213 | 4/20 | 0.49 |
| ▸ | TEK | Q02763 | 4/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 8/20 | 0.41 |
| ▸ | CHUK | O15111 | 5/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401975 | 0.90 | KDR (0.47) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6401060 | 0.88 | KDR (0.48) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6394323 | 0.87 | KDR (0.47) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6313981 | 0.86 | KDR (0.45) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6729223 | 0.84 | KDR (0.57) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6404350 | 0.84 | KDR (0.54) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6399454 | 0.83 | KDR (0.65) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6728908 | 0.83 | KDR (0.54) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6394106 | 0.82 | KDR (0.52) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6392117 | 0.81 | KDR (0.47) | KDRINSRTEKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | KDR 2/4885INSR 358/4885TEK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.